Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
-
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
-
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
-
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
-
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
-
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
-
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
-
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
-
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.
-
NurExone has been awarded a grant by the Israel Innovation Authority (“IIA”) as part of the Israel-Canada bilateral Eureka program